CELIAFLORA Junior
Pediatrics
- Reduces intestinal inflammation
- Supports restoration of intestinal barrier function
- Promotes a balanced intestinal flora
Bifidobacterium breve BR03 (DSM 16604)
Bifidobacterium breve B632 (DSM 24706)
Food supplement with probiotic strains.
Biotin
EFSA Claim: contributes to the mantainance of normal mucosa.
Celiac disease (CD), with a global prevalence of 1-2%, affects both adults and children [1]. An altered gut microbiota is a characteristic feature of CD, often showing a decreased abundance of beneficial bacteria. Specifically, in breastfed infants at genetic risk for CD, there is often a lower abundance of Bifidobacterium species and an increased Firmicutes to Bacteroidetes ratio, along with a significantly higher abundance of Gram-negative bacteria and E. coli. A similar decrease in Bifidobacterium species has been observed in various autoimmune conditions like rheumatoid arthritis, suggesting a potential protective role against inflammation.
CELIAFLORA™ Junior has been specially formulated to address these microbiota imbalances in pediatric CD patients [2-6]. It aims to:
Rebalance gut dysbiosis.
Help counteract intestinal inflammation.
Repair disrupted intestinal permeability integrity.
Two strains, Bifidobacterium breve BR03 and Bifidobacterium breve B632, have been chosen for their efficacy in:
Reaching and colonizing the intestines of babies and children [2].
Counteracting gut inflammation [4].
Exerting strong direct inhibition against various pathogenic microorganisms, including Enterobacteriaceae [3].
CELIAFLORA™ Junior's benefits are supported by in vitro, preclinical, and clinical studies. In a gluten-sensitive mouse model, CELIAFLORA™ Junior effectively mitigated the toxic effects of active gliadin peptides, a key factor in CD [4]. It significantly inhibited gut inflammation, reduced all markers of intestinal inflammation, and consistently inhibited the intestinal permeability abnormality induced by gliadin active peptides, thereby completely reversing gliadin-mediated tissue damage.
In two clinical studies involving pediatric patients with celiac disease, daily supplementation with CELIAFLORA™ Junior for three months successfully re-established the Firmicutes/Bacteroidetes ratio and reduced TNFα production [5,6]. These findings demonstrate that CELIAFLORA™ Junior can effectively counteract the pro-inflammatory environment in children with celiac disease.
1. Prashant Singh et al. Global Prevalence of Celiac Disease: Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2018 Jun;16(6):823-836.e2. Doi: 10.1016/j.cgh.2017.06.037
2. Mogna L. et al. Capability of the two microorganisms Bifidobacterium breve B632 and Bifidobacterium breve BR03 to colonize the intestinal microbiota of children. J Clin Gastroenterol. 2014;48 Suppl 1:S37-S39. doi:10.1097/MCG.0000000000000234
3. Simone M. et al. The probiotic Bifidobacterium breve B632 inhibited the growth of Enterobacteriaceae within colicky infant microbiota cultures. Biomed Res Int. 2014;2014:301053. doi: 10.1155/2014/301053.
4. Ferrari E. et al. Probiotics Supplements Reduce ER Stress and Gut Inflammation Associated with Gliadin Intake in a Mouse Model of Gluten Sensitivity. Nutrients. 2021 Apr 7;13(4):1221. doi: 10.3390/nu13041221.
5. Klemenak M. et al. Administration of Bifidobacterium breve Decreases the Production of TNF-α in Children with Celiac Disease. Dig Dis Sci. 2015 Nov;60(11):3386-92. doi: 10.1007/s10620-015-3769-7.
6. Quagliariello A. et al. Effect of Bifidobacterium breve on the Intestinal Microbiota of Coeliac Children on a Gluten Free Diet: A Pilot Study. Nutrients. 2016;8(10):660. Published 2016 Oct 22. doi:10.3390/nu8100660
